CAMBRIDGE, Mass. & PARIS–(BUSINESS WIRE)–Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics
company, and Sanofi
announced today a strategic restructuring of their RNAi therapeutics
alliance to streamline and optimize development and commercialization of
certain products for the treatment of rare genetic diseases.
Specifically, Alnylam will obtain global development and
commercialization rights to its investigational RNAi therapeutics
programs for the treatment of ATTR amyloidosis, including patisiran and
ALN-TTRsc02. Sanofi will receive royalties based on net sales of these
ATTR amyloidosis products. Sanofi will obtain global …
Read the full article at: https://www.businesswire.com/news/home/20180107005093/en/Alnylam-Sanofi-Enter-Strategic-Restructuring-RNAi-Therapeutics